Cargando…
Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer
BACKGROUND: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were inc...
Autores principales: | Pelissier, Aurélie, Roulot, Aurélie, Guéry, Béatrice, Bonneau, Claire, Bellet, Dominique, Rouzier, Roman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039904/ https://www.ncbi.nlm.nih.gov/pubmed/27677313 http://dx.doi.org/10.1186/s13048-016-0270-7 |
Ejemplares similares
-
Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022) -
Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
por: Rong, Yan, et al.
Publicado: (2021) -
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016) -
Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023) -
Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)